Icecure Medical Ltd. Stock Price, News & Analysis

IceCure Medical (NASDAQ: ICCM), a developer of cryoablation technology for tumor treatment, released preliminary financial results for Q2 and H1 2025. The company expects Q2 2025 product sales of $525,000, with over $200,000 in delayed shipments moving to Q3 2025 due to temporary logistics issues related to the Israel-Iran conflict.

For H1 2025, product sales reached approximately $1.25 million, down from $1.65 million in H1 2024. The company maintains that order flow remained stable despite regional conflicts, with delays primarily affecting non-U.S. markets. U.S. operations continued normally due to sufficient ProSense® inventory. Complete Q2 and H1 2025 financial results will be released in August 2025.

IceCure Medical (NASDAQ: ICCM), a developer of cryoablation technology for tumor treatment, has announced a rights offering to raise up to $10 million. Shareholders of record as of July 9, 2025, will receive one subscription right for each ordinary share, allowing them to subscribe for 0.1703 units at $1.00 per unit.

Each unit consists of one ordinary share and a warrant to purchase one ordinary share. Epoch Partner Investments, IceCure's largest shareholder, has committed to participate with up to $5 million. The proceeds will be used to repay a $2 million bridge loan from Epoch and for general corporate purposes. The subscription period runs from July 10 to July 28, 2025.

IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from the USPTO for its 'Cryogen Flow Control' patent, extending protection until 2045. The patent, already granted in Japan and pending in EU and other markets, enhances the company's cryoablation technology that destroys tumors through freezing. The innovation focuses on precise temperature control using sensor data to regulate cryogen flow, improving treatment effectiveness. IceCure, with over 20 patents in the U.S., is currently awaiting FDA marketing approval for ProSense® in early-stage breast cancer treatment for women over 70 when combined with adjuvant endocrine therapy. CEO Eyal Shamir emphasizes this patent's importance in expanding treatment indications and strengthening their position as a global leader in liquid nitrogen-based cryoablation technology.

IceCure Medical (NASDAQ: ICCM) reported Q1 2025 financial results and key developments for its ProSense® cryoablation technology. The company has submitted its post-market study plan to the FDA, awaiting marketing authorization for ProSense® in treating early-stage low-risk breast cancer in women aged 70+. Q1 financial highlights include: revenue of $725,000 (2% YoY decrease), gross profit of $218,000 with 30% margin, and a narrowed net loss of $3.588 million. The company secured a $2 million unsecured loan from its largest investor and raised $2.65 million through ATM offerings. Cash position stands at $6.2 million as of May 27, 2025. ProSense® gained significant recognition at multiple medical conferences and showed promising results in various studies, including an 88.7% recurrence-free rate in kidney cancer trials.

IceCure Medical (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, has announced it will release its Q1 2025 financial and operational results on May 28, 2025, before the Nasdaq market opens. The company will host a conference call and webcast at 10:00 AM EDT on the same day to discuss the results and other corporate developments. Investors can join via US number (1-888-407-2553) or International number (+972-3-918-0696). A live webcast will be available, and a recording will be accessible on the company's investor relations website.

IceCure Medical (NASDAQ: ICCM) reported strong interest from breast surgeons at the ASBrS 2025 Annual Meeting following recent positive FDA developments for their ProSense® cryoablation system. The company's ICE3 study was recognized as one of the "Best Papers of 2024" and received favorable mention during the ASBrS Presidential Address.

The FDA has requested a post-market study for ProSense® in treating early-stage low-risk breast cancer in women aged 70+ when combined with adjuvant endocrine therapy. The planned study will include 400 patients across 25 sites. The company's participation at ASBrS included system demonstrations, ultrasound course training, and an expert booth meeting featuring former ASBrS President Dr. Nathalie Johnson.

IceCure Medical has made significant progress with the FDA regarding its ProSense® cryoablation system for treating early-stage breast cancer in women aged 70 and over. Following a productive meeting with the FDA's Center for Devices and Radiological Health, the company is preparing for a post-market study as part of its De Novo marketing authorization process.

The planned study will involve 400 patients across 25 sites in the U.S., targeting approximately 46,000 potential patients annually. ProSense® aims to become the first minimally invasive alternative to lumpectomy, offering treatment as an outpatient procedure. The company will submit its post-market study plan within weeks and is actively recruiting clinical sites and doctors at the American Society of Breast Surgeons Annual Meeting.

Procedures will be eligible for reimbursement under the CPT III code, covering $3,800 in facility costs. IceCure's U.S. sales team is prepared for commercialization once final marketing authorization is granted, pending FDA approval of the post-market study plan.

IceCure Medical (Nasdaq: ICCM) participated in the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium in Colorado Springs, showcasing their ProSense® cryoablation technology. The company sponsored two sold-out breast cryoablation courses featuring hands-on training with ProSense® on April 24 and 26, 2025.

The event included a VIP Exhibitor Hour featuring Dr. Robert Ward, Assistant Professor at Brown University and Program Director for Breast Imaging Fellowship, who has published research on breast cancer cryoablation using ProSense®. The strong attendance demonstrates growing interest from radiologists in integrating ProSense® into their clinics, with medical societies increasingly incorporating cryoablation into their curriculum.

IceCure Medical's ProSense® cryoablation system was prominently featured at ECIO 2025 in Rotterdam, with a major focus on breast cancer treatment. The conference highlighted several key studies demonstrating ProSense®'s effectiveness:

The THERMAC trial showed 94% efficacy rate, 0% complications, and 95% of patients preferring cryoablation over traditional surgery. A study by Prof. Vogl demonstrated 2.9 years mean progression-free survival in 45 patients with 56 tumors.

Another significant study comparing treatment methods revealed that cryoablation combined with hormonal therapy achieved 94% tumor size reduction, outperforming both standalone treatments. The conference included hands-on device training sessions and expert exchanges, highlighting ProSense®'s growing adoption in European markets.